Edan Instruments, Inc. Class A

Edan Instruments, Inc. Class A

SSZSE:300206
11.88
CNY
+0.13
(+1.11%)
0.65EPS
18.31P/E
6.76BMarket Cap
Apr 01Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.79
0.93
0.94
1.19
1.44
1.7
1.95
3.99
2.82
3.01
3.34
3.16
3.45
3.72
Basic EPS, GAAP
0.06
0.02
0.18
0.04
0.07
0.16
0.23
1.12
0.4
0.4
0.38
0.28
0.53
0.64
Free Cash Flow per Basic Share
-0.15
-0.18
-0.14
-0.26
0.12
0.08
0.11
1.1
0.28
0.51
0.17
0.51
0.46
- -
Dividend per Share
0.05
0.05
0.04
0.09
0.04
0.09
0.1
0.17
0.44
0.21
0.21
0.21
0.21
- -
Book Value per Share
2.01
1.99
2.03
2.06
2.11
2.13
2.22
3.11
2.98
3.19
3.38
3.45
3.78
4.03
Tangible Book Value per Share
1.9
1.89
1.67
1.72
1.79
1.87
1.91
2.87
2.74
2.98
3.21
3.32
3.67
3.93
Basic Weighted Avg Shares
578
560
585
586
585
585
583
582
580
580
580
580
580
580
Sales/Revenue/Turnover
455
523
550
698
843
993
1,136
2,319
1,636
1,742
1,938
1,834
1,999
2,158
Operating Margin (%)
-0.85
-5.68
-8.45
-1.77
6.97
9.38
10.62
34.3
16.98
12.88
10.84
9.12
15.87
19.94
Depreciation Expense
13
16
19
29
36
38
39
43
50
55
53
55
55
- -
Net Income, GAAP
35
13
103
26
44
93
132
653
231
233
221
162
306
370
Effective Tax Rate (%)
1.19
0.05
- -
- -
- -
- -
0.33
13.69
8.06
4.6
- -
1.86
2.59
7.01
Profit Margin (%)
7.63
2.57
18.76
3.78
5.19
9.33
11.6
28.17
14.14
13.37
11.42
8.84
15.29
17.12
Working Capital
986
937
763
602
626
676
684
1,201
1,098
1,226
1,340
1,336
1,480
1,618
LT Debt
- -
60
45
- -
- -
- -
- -
7
8
5
11
11
20
17
Total Equity
1,180
1,163
1,216
1,226
1,252
1,258
1,299
1,812
1,732
1,851
1,964
2,008
2,194
2,341
Return on Invested Capital (%)
1.21
-0.85
- -
- -
- -
- -
10.61
39.78
12.01
12.56
- -
8.04
14.34
16.5
Return on Capital (%)
1.21
1.36
- -
- -
- -
- -
10.67
40.92
12.77
12.8
- -
8.09
14.34
16.55
Return on Common Equity (%)
2.96
1.15
8.79
2.21
3.59
7.47
10.4
42.12
13.06
12.99
11.59
8.16
14.55
16.88

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
10
11
11
LT Borrowings
- -
- -
- -
LT Finance Leases
18
19
17
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
580
580
580
Market Capitalization
7,582
7,089
6,765

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,870
1,835
1,989
Cash, Cash Equivalents & STI
1,263
1,212
1,275
Accounts Receivable, Net
214
192
260
Inventories
347
377
396
Total Current Liabilities
293
343
371
Payables & Accruals
- -
- -
- -
ST Debt
10
11
11
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
6.63%
4.01%
9.27%
Free Cash Flow
98.49%
24.78%
-8.68%
Net Income, GAAP
53.39%
-1.43%
88.54%
Sales/Revenue/Turnover
17.58%
-1.62%
8.97%
Total Cash Common Dividend
- -
- -
0.36%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
444
479
460
452
1,834
2025
420
493
- -
553
1,999
2026
516
507
582
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.07
0.15
0.08
-0.02
0.28
2025
0.11
0.15
- -
0.08
0.53
2026
0.18
0.17
0.2
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.21
2025
- -
- -
- -
- -
0.21
2026
- -
- -
- -
- -
- -

Company Description

CEO
Hao Zhang
Full Time Employees
2,475
Sector
Health technology
Industry
Medical specialties
Address
Jinsha Community Shenzhen GD China 518122
IPO Date
Apr 12, 2011
Business
Edan Instruments, Inc. Edan Instruments, Inc. engages in the research, development, manufacture, and service of medical electronic equipment and in vitro diagnostic products principally in China and internationally. Founded in 1995 and headquartered in Shenzhen, China, the company offers a comprehensive portfolio of core products and solutions across patient monitoring, including modular and compact patient monitors, vital signs monitors, telemetry systems, and IT integration products; electrocardiogram (ECG) diagnosis, encompassing resting ECG, stress test, Holter monitoring, wireless solutions, and ECG workstations; obstetrics and gynecology devices, such as fetal and maternal monitoring systems, fetal telemetry, ultrasonic Doppler systems, central monitoring stations, video colposcopes, and biofeedback/stimulation systems; ultrasound imaging systems comprising cart-based color Doppler, portable color Doppler, and black-and-white ultrasound; in-vitro diagnostics featuring hematology analyzers and reagents; point-of-care testing with blood gas and chemistry analyzers, molecular diagnostic systems, disposable arterial blood samplers, and blood gas capillary tubes; as well as veterinary ultrasound, ECG, laboratory, and monitoring products. Edan Instruments operates globally, serving customers in over 120 countries through subsidiaries and facilities including EDAN Diagnostics, Inc. in San Diego, California; EDAN Instruments GmbH in Germany; and entities in France, Indonesia, Peru, Thailand, Kenya, the United Kingdom, Russia, and India. Among its latest major developments, the company opened a new U.S. manufacturing hub in San Diego on September 30, 2025, integrating production, logistics, R&D, and support to enhance North American supply chain resilience; entered a collaboration with Global Health Labs in March 2024 to co-develop AI-enabled ultrasound devices targeting low- and middle-income countries; announced the acquisition by EDAN Diagnostics of a molecular diagnostic point-of-care platform from LGC, including ongoing assay development partnerships; and launched innovations such as the iV100 patient monitor and advanced clinical care devices at the 2025 China International Medical Equipment Fair.

Company News

  • EDAN Forays into Molecular Point-of-Care Market with Its First-Ever Molecular Diagnostics Solution Released at Medlab Asia 2022